Market Scenario:
The global neuropathic pain market is predicted to exhibit a 6.06% CAGR from 2018 to 2023 (forecast period) owing to the uptick noticed in cancer and diabetes cases. Neuropathic pain is pain which can be caused by peripheral nerve problems. High demand for novel treatment methods for the pain is likely to spur market growth over the forecast period. The emergence of pain management centers and demand for generic drugs to alleviate pain levels are factors which can further the global market till 2023.

Segmentation
By type, the neuropathic pain market is segmented into peripheral neuropathy, entrapment neuropathy, post traumatic neuropathy, phantom limb pain, post herpetic neuralgia (PHN), and trigeminal neuralgia. By indication, the market is segmented into spinal stenosis, diabetic neuropathy, and chemotherapy-induced peripheral neuropathy.
Methods of diagnosis discussed in the report include imaging, blood tests, and physical examination. By treatment, the neuropathic pain market is segmented into multimodal therapy and medication type. The latter is further segmented into NSAIDs Type, nerve blocks type, and antidepressant drugs type.

Regional Analysis
he neuropathic pain market covers the latest trends and opportunities across Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).
The Americas accounted for 37.03% share of the market in 2017. The increase in numbers of the elderly populace coupled with prevalence of neuropathic pain is likely to drive market demand till 2023. Well-defined healthcare infrastructure and presence of various players in the region are likely to assist the market in generating USD 2,226.8 million by 2023.
Europe accounted for 35.12% share in 2017. Supportive policies outlined by the World Health Organization (WHO) and Centers for Disease Control & Prevention (CDC) to create awareness among consumers is likely to assist the region net a massive revenue of USD 2,844.49 million by 2023

Key Players for global wireless health and fitness devices market
Key players in the neuropathic pain market include Depomed Inc. (U.S.), AstraZeneca (U.K.), Baxter Healthcare Corporation (U.S.), Johnson & Johnson Services Inc. (U.S.), Astellas Pharma Inc. (Tokyo), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Biogen Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), and Abbott Laboratories (U.S.).

Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/581 .